Strs Ohio Sells 7,612 Shares of Bioventus Inc. (NYSE:BVS)

Strs Ohio cut its position in shares of Bioventus Inc. (NYSE:BVSGet Rating) by 22.3% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 26,500 shares of the company’s stock after selling 7,612 shares during the period. Strs Ohio’s holdings in Bioventus were worth $373,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also modified their holdings of BVS. Royce & Associates LP bought a new stake in Bioventus in the fourth quarter valued at $25,911,000. Tamarack Advisers LP grew its position in Bioventus by 82.3% in the fourth quarter. Tamarack Advisers LP now owns 875,000 shares of the company’s stock valued at $12,679,000 after acquiring an additional 395,000 shares during the period. Soleus Capital Management L.P. grew its position in Bioventus by 352.8% in the fourth quarter. Soleus Capital Management L.P. now owns 428,397 shares of the company’s stock valued at $6,207,000 after acquiring an additional 333,795 shares during the period. Stephens Inc. AR bought a new stake in Bioventus in the fourth quarter valued at $2,675,000. Finally, Rice Hall James & Associates LLC grew its position in Bioventus by 44.6% in the fourth quarter. Rice Hall James & Associates LLC now owns 536,098 shares of the company’s stock valued at $7,768,000 after acquiring an additional 165,269 shares during the period. 86.85% of the stock is currently owned by institutional investors.

Bioventus Price Performance

Shares of BVS stock opened at $7.27 on Tuesday. The stock’s fifty day moving average is $8.41 and its 200-day moving average is $11.43. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.05 and a current ratio of 1.43. The stock has a market capitalization of $560.86 million, a PE ratio of -22.03 and a beta of 1.88. Bioventus Inc. has a 52 week low of $6.30 and a 52 week high of $17.64.

Bioventus (NYSE:BVSGet Rating) last announced its earnings results on Tuesday, May 10th. The company reported $0.04 EPS for the quarter, topping the consensus estimate of $0.01 by $0.03. The company had revenue of $117.29 million for the quarter, compared to analysts’ expectations of $118.09 million. Bioventus had a positive return on equity of 12.58% and a negative net margin of 5.29%. During the same quarter in the prior year, the business earned ($0.02) earnings per share. Equities research analysts expect that Bioventus Inc. will post 0.75 EPS for the current fiscal year.

Analysts Set New Price Targets

Separately, The Goldman Sachs Group lowered their price target on Bioventus from $19.00 to $17.00 and set a “neutral” rating on the stock in a research report on Monday, March 21st.

Bioventus Company Profile

(Get Rating)

Bioventus Inc a medical device company, focuses on developing and commercializing clinical treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical joint pain injection therapies, as well as peripheral nerve stimulation products.

Further Reading

Want to see what other hedge funds are holding BVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bioventus Inc. (NYSE:BVSGet Rating).

Institutional Ownership by Quarter for Bioventus (NYSE:BVS)

Receive News & Ratings for Bioventus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioventus and related companies with MarketBeat.com's FREE daily email newsletter.